Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing
Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether impaired intestinal permeability contributes to these symptoms. We performed a prospective study of intestinal permeability, measured by end...
Saved in:
Published in | Gastroenterology (New York, N.Y. 1943) Vol. 153; no. 3; pp. 723 - 731.e1 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.09.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether impaired intestinal permeability contributes to these symptoms.
We performed a prospective study of intestinal permeability, measured by endoscopic confocal laser endomicroscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn’s disease [CD], and 22 healthy individuals [controls]) in Sydney, Australia from May 2009 and September 2015. Symptomatic CD was defined by a CD Activity Index score of 150 or more and symptomatic UC by a partial Mayo score of 2 or more. Mucosal healing was defined as CD Endoscopic Index of Severity of 0 in CD or Mayo endoscopic sub-score of 0–1 for patients with UC. Intestinal permeability was quantified by the Confocal Leak Score (CLS; range: 0=no impaired permeability to 100=complete loss of barrier function). The primary endpoint was intestinal permeability in patients with symptomatic IBD in mucosal healing vs patients with asymptomatic IBD in mucosal healing. We determined the sensitivity and specificity of CLS in determining symptoms based on receiver operating characteristic analysis.
Ongoing bowel symptoms were present in 16.3% of patients with IBD and mucosal healing (15.4% of patients with CD, 17.4% with UC). Patients with symptomatic IBD had a significantly higher median CLS (19.0) than patients with asymptomatic IBD (7.3; P < .001) or controls (5.9, P < .001). There were no significant differences between patients with IBD in remission vs controls (P = .261). Median CLS was significantly higher in patients with symptomatic than asymptomatic CD (17.7 vs 8.1; P = .009) and patients with symptomatic than asymptomatic UC (22.2 vs 6.9; P = .021). A CLS of 13.1 or more identified ongoing bowel symptoms in patients with IBD and mucosal healing with 95.2% sensitivity and 97.6% specificity; the receiver operating characteristic area under curve value was 0.88. Based on this cutoff, 36.2% of patients with IBD in mucosal healing have increased intestinal permeability. On regression analysis, every increase in CLS of 1.9 correlated with an additional diarrheal motion per day (P = .008).
In a prospective study of intestinal permeability in patients with IBD and mucosal healing, we associated impaired intestinal permeability with ongoing bowel symptoms; increases in permeability correlated with increased severity of diarrhea. Resolution of mucosal permeability beyond mucosal healing might improve outcomes of patients with IDB (ANZCTR.org.au: ACTRN12613001248752). |
---|---|
AbstractList | Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether impaired intestinal permeability contributes to these symptoms.
We performed a prospective study of intestinal permeability, measured by endoscopic confocal laser endomicroscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn’s disease [CD], and 22 healthy individuals [controls]) in Sydney, Australia from May 2009 and September 2015. Symptomatic CD was defined by a CD Activity Index score of 150 or more and symptomatic UC by a partial Mayo score of 2 or more. Mucosal healing was defined as CD Endoscopic Index of Severity of 0 in CD or Mayo endoscopic sub-score of 0–1 for patients with UC. Intestinal permeability was quantified by the Confocal Leak Score (CLS; range: 0=no impaired permeability to 100=complete loss of barrier function). The primary endpoint was intestinal permeability in patients with symptomatic IBD in mucosal healing vs patients with asymptomatic IBD in mucosal healing. We determined the sensitivity and specificity of CLS in determining symptoms based on receiver operating characteristic analysis.
Ongoing bowel symptoms were present in 16.3% of patients with IBD and mucosal healing (15.4% of patients with CD, 17.4% with UC). Patients with symptomatic IBD had a significantly higher median CLS (19.0) than patients with asymptomatic IBD (7.3; P < .001) or controls (5.9, P < .001). There were no significant differences between patients with IBD in remission vs controls (P = .261). Median CLS was significantly higher in patients with symptomatic than asymptomatic CD (17.7 vs 8.1; P = .009) and patients with symptomatic than asymptomatic UC (22.2 vs 6.9; P = .021). A CLS of 13.1 or more identified ongoing bowel symptoms in patients with IBD and mucosal healing with 95.2% sensitivity and 97.6% specificity; the receiver operating characteristic area under curve value was 0.88. Based on this cutoff, 36.2% of patients with IBD in mucosal healing have increased intestinal permeability. On regression analysis, every increase in CLS of 1.9 correlated with an additional diarrheal motion per day (P = .008).
In a prospective study of intestinal permeability in patients with IBD and mucosal healing, we associated impaired intestinal permeability with ongoing bowel symptoms; increases in permeability correlated with increased severity of diarrhea. Resolution of mucosal permeability beyond mucosal healing might improve outcomes of patients with IDB (ANZCTR.org.au: ACTRN12613001248752). Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether impaired intestinal permeability contributes to these symptoms.BACKGROUND & AIMSMany patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether impaired intestinal permeability contributes to these symptoms.We performed a prospective study of intestinal permeability, measured by endoscopic confocal laser endomicroscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn's disease [CD], and 22 healthy individuals [controls]) in Sydney, Australia from May 2009 and September 2015. Symptomatic CD was defined by a CD Activity Index score of 150 or more and symptomatic UC by a partial Mayo score of 2 or more. Mucosal healing was defined as CD Endoscopic Index of Severity of 0 in CD or Mayo endoscopic sub-score of 0-1 for patients with UC. Intestinal permeability was quantified by the Confocal Leak Score (CLS; range: 0=no impaired permeability to 100=complete loss of barrier function). The primary endpoint was intestinal permeability in patients with symptomatic IBD in mucosal healing vs patients with asymptomatic IBD in mucosal healing. We determined the sensitivity and specificity of CLS in determining symptoms based on receiver operating characteristic analysis.METHODSWe performed a prospective study of intestinal permeability, measured by endoscopic confocal laser endomicroscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn's disease [CD], and 22 healthy individuals [controls]) in Sydney, Australia from May 2009 and September 2015. Symptomatic CD was defined by a CD Activity Index score of 150 or more and symptomatic UC by a partial Mayo score of 2 or more. Mucosal healing was defined as CD Endoscopic Index of Severity of 0 in CD or Mayo endoscopic sub-score of 0-1 for patients with UC. Intestinal permeability was quantified by the Confocal Leak Score (CLS; range: 0=no impaired permeability to 100=complete loss of barrier function). The primary endpoint was intestinal permeability in patients with symptomatic IBD in mucosal healing vs patients with asymptomatic IBD in mucosal healing. We determined the sensitivity and specificity of CLS in determining symptoms based on receiver operating characteristic analysis.Ongoing bowel symptoms were present in 16.3% of patients with IBD and mucosal healing (15.4% of patients with CD, 17.4% with UC). Patients with symptomatic IBD had a significantly higher median CLS (19.0) than patients with asymptomatic IBD (7.3; P < .001) or controls (5.9, P < .001). There were no significant differences between patients with IBD in remission vs controls (P = .261). Median CLS was significantly higher in patients with symptomatic than asymptomatic CD (17.7 vs 8.1; P = .009) and patients with symptomatic than asymptomatic UC (22.2 vs 6.9; P = .021). A CLS of 13.1 or more identified ongoing bowel symptoms in patients with IBD and mucosal healing with 95.2% sensitivity and 97.6% specificity; the receiver operating characteristic area under curve value was 0.88. Based on this cutoff, 36.2% of patients with IBD in mucosal healing have increased intestinal permeability. On regression analysis, every increase in CLS of 1.9 correlated with an additional diarrheal motion per day (P = .008).RESULTSOngoing bowel symptoms were present in 16.3% of patients with IBD and mucosal healing (15.4% of patients with CD, 17.4% with UC). Patients with symptomatic IBD had a significantly higher median CLS (19.0) than patients with asymptomatic IBD (7.3; P < .001) or controls (5.9, P < .001). There were no significant differences between patients with IBD in remission vs controls (P = .261). Median CLS was significantly higher in patients with symptomatic than asymptomatic CD (17.7 vs 8.1; P = .009) and patients with symptomatic than asymptomatic UC (22.2 vs 6.9; P = .021). A CLS of 13.1 or more identified ongoing bowel symptoms in patients with IBD and mucosal healing with 95.2% sensitivity and 97.6% specificity; the receiver operating characteristic area under curve value was 0.88. Based on this cutoff, 36.2% of patients with IBD in mucosal healing have increased intestinal permeability. On regression analysis, every increase in CLS of 1.9 correlated with an additional diarrheal motion per day (P = .008).In a prospective study of intestinal permeability in patients with IBD and mucosal healing, we associated impaired intestinal permeability with ongoing bowel symptoms; increases in permeability correlated with increased severity of diarrhea. Resolution of mucosal permeability beyond mucosal healing might improve outcomes of patients with IDB (ANZCTR.org.au: ACTRN12613001248752).CONCLUSIONSIn a prospective study of intestinal permeability in patients with IBD and mucosal healing, we associated impaired intestinal permeability with ongoing bowel symptoms; increases in permeability correlated with increased severity of diarrhea. Resolution of mucosal permeability beyond mucosal healing might improve outcomes of patients with IDB (ANZCTR.org.au: ACTRN12613001248752). Abstract Background & Aims Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether impaired intestinal permeability contributes to these symptoms. Methods We performed a prospective study of intestinal permeability, measured by endoscopic confocal laser endomicroscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn’s disease [CD], and 22 healthy individuals [controls]) in Sydney Australia from May 2009 and September 2015. Symptomatic CD was defined by a CD Activity Index score of 150 or more and symptomatic UC by a partial Mayo score of 2 or more. Mucosal healing was defined as CD Endoscopic Index of Severity of 0 in CD or Mayo endoscopic sub-score of 0–1 for patients with UC. Intestinal permeability was quantified by the Confocal Leak Score (CLS, range: 0=no impaired permeability to 100=complete loss of barrier function). The primary endpoint was intestinal permeability in patients with symptomatic IBD in mucosal healing vs patients with asymptomatic IBD in mucosal healing. We determined the sensitivity and specificity of CLS in determining symptoms based on receiver operating characteristic (ROC) analysis. Results Ongoing bowel symptoms were present in 16.3% of patients with IBD and mucosal healing (15.4% of patients with CD and 17.4% with UC). Patients with symptomatic IBD had a significantly higher median CLS (19.0) than patients with asymptomatic IBD (7.3, P <.001) or controls (5.9, P <.001). There were no significant differences between patients with IBD in remission vs controls ( P =.261). The median CLS was significantly higher in patients with symptomatic than asymptomatic CD (17.7 vs 8.1, P =.009) and patients with symptomatic than asymptomatic UC (22.2 vs 6.9, P =.021). A CLS of 13.1 or more identified ongoing bowel symptoms in patients with IBD and mucosal healing with 95.2% sensitivity and 97.6% specificity; the ROC area under curve value was 0.88. Based on this cutoff, 36.2% of patients with IBD in mucosal healing have increased intestinal permeability. On regression analysis, every increase in CLS of 1.9 correlated with an additional diarrheal motion per day ( P =.008). Conclusions In a prospective study of intestinal permeability in patients with IBD and mucosal healing, we associated impaired intestinal permeability with ongoing bowel symptoms ; increases in permeability correlated with increased severity of diarrhea. Resolution of mucosal permeability beyond mucosal healing might improve outcomes of patients with IDB. ANZCTR.org.au: ACTRN12613001248752 |
Author | Chang, Jeff Leong, Rupert W. Phan, Tri Giang Ip, Matthew Yang, Michael Wasinger, Valerie C. |
Author_xml | – sequence: 1 givenname: Jeff surname: Chang fullname: Chang, Jeff organization: Gastroenterology and Liver Services, Bankstown Hospital, South Western Sydney Local Health District, Sydney, Australia – sequence: 2 givenname: Rupert W. orcidid: 0000-0001-5944-3488 surname: Leong fullname: Leong, Rupert W. email: rupertleong@outlook.com organization: Gastroenterology and Liver Services, Bankstown Hospital, South Western Sydney Local Health District, Sydney, Australia – sequence: 3 givenname: Valerie C. surname: Wasinger fullname: Wasinger, Valerie C. organization: Bioanalytical Mass Spectrometry Facility, UNSW Australia, Sydney, Australia – sequence: 4 givenname: Matthew surname: Ip fullname: Ip, Matthew organization: Gastroenterology and Liver Services, Bankstown Hospital, South Western Sydney Local Health District, Sydney, Australia – sequence: 5 givenname: Michael surname: Yang fullname: Yang, Michael organization: Gastroenterology and Liver Services, Bankstown Hospital, South Western Sydney Local Health District, Sydney, Australia – sequence: 6 givenname: Tri Giang orcidid: 0000-0002-4909-2984 surname: Phan fullname: Phan, Tri Giang organization: Faculty of Medicine, UNSW Australia, Sydney, Australia |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28601482$$D View this record in MEDLINE/PubMed |
BookMark | eNqVUtGK1DAUDbLizq7-gUgefemYNE2bigg6ru7Ayi6s4mPIpLdjxjQZk1TpD-x3mzKjD4IswoX7kHPOJeecM3TivAOEnlKypISzF7vlVsUU_LIktFkSnqd-gBaUl6IghJYnaJFXXXAi-Ck6i3FHCGmZoI_QaSlqQitRLtDdetgrE6DDa5cgJuOUxTcQBlAbY02a8Mq7FMxmzK84eXzttt64LX7rf4LFt9OwT36I2Dh8o5IBlyL-YtLXLNdbNQwq-TAdwe9MBBUBK9fhj6P2MZ-6BGWz3GP0sFc2wpPjPkef3198Wl0WV9cf1qs3V4WuGpIK3quW1rVWqgQQVOiecV43fQesJDXTfSvaBqq-6QGIpq2ugNCNIG3JOIAW7Bw9P-jug_8-5v_KwUQN1ioHfoyStkQ0LWvLGfrsCB03A3RyH8ygwiR_e5cB1QGgg48xQP8HQomcI5I7eYhIzhFJwvPUmfbyL5o2KVs326yMvY_8-kCGbNIPA0FGnU3X0OUMdZKdN_8roLP_Riv7DSaIOz-G3IBshIylJPJ2rtDcINow3jBKs8Crfwvcf_8XS5va2A |
CitedBy_id | crossref_primary_10_1093_ibd_izae238 crossref_primary_10_1155_2018_3048532 crossref_primary_10_1016_j_ctrv_2022_102406 crossref_primary_10_3389_fgstr_2022_959082 crossref_primary_10_1002_bdd_2220 crossref_primary_10_4166_kjg_2022_001 crossref_primary_10_1007_s11655_022_3531_x crossref_primary_10_1016_j_phymed_2021_153590 crossref_primary_10_3390_nu10111684 crossref_primary_10_1186_s40779_021_00341_4 crossref_primary_10_23736_S2724_5985_22_03215_6 crossref_primary_10_3390_nu10081016 crossref_primary_10_1016_j_cgh_2020_03_044 crossref_primary_10_1016_j_giec_2019_02_004 crossref_primary_10_1016_j_cgh_2018_08_001 crossref_primary_10_3390_immuno1040039 crossref_primary_10_3390_antiox9100926 crossref_primary_10_3390_molecules24030513 crossref_primary_10_1016_j_jare_2022_03_010 crossref_primary_10_1111_apt_14368 crossref_primary_10_1016_j_heliyon_2023_e22186 crossref_primary_10_1038_s41598_021_92262_4 crossref_primary_10_3390_nu16183173 crossref_primary_10_1016_j_jep_2024_118570 crossref_primary_10_3390_cells9081793 crossref_primary_10_34215_1609_1175_2019_4_5_9 crossref_primary_10_3390_ijms241512078 crossref_primary_10_3923_pjbs_2022_313_321 crossref_primary_10_1016_j_imlet_2022_07_006 crossref_primary_10_3389_fcell_2023_1223032 crossref_primary_10_3923_pjn_2021_46_54 crossref_primary_10_1016_j_jpain_2022_09_016 crossref_primary_10_1007_s11356_023_30542_4 crossref_primary_10_1021_acs_jafc_4c04933 crossref_primary_10_1038_s41598_020_71198_1 crossref_primary_10_1111_1541_4337_12652 crossref_primary_10_1126_sciadv_ado8222 crossref_primary_10_3389_fcell_2023_1132905 crossref_primary_10_1016_j_intimp_2024_111886 crossref_primary_10_1152_ajpgi_00104_2019 crossref_primary_10_1016_j_intimp_2021_108091 crossref_primary_10_1038_s41419_022_04566_6 crossref_primary_10_3390_ijms25115817 crossref_primary_10_1002_ncp_10489 crossref_primary_10_1055_a_2208_7019 crossref_primary_10_1093_abbs_gmab116 crossref_primary_10_3390_ijms231911162 crossref_primary_10_3390_ijms26062466 crossref_primary_10_1186_s12906_019_2749_4 crossref_primary_10_1016_j_micres_2024_127928 crossref_primary_10_1038_s41598_020_78141_4 crossref_primary_10_3390_diagnostics14151606 crossref_primary_10_1016_j_gastha_2023_11_005 crossref_primary_10_4291_wjgp_v11_i6_114 crossref_primary_10_1038_s41598_024_60959_x crossref_primary_10_1016_j_ebiom_2022_103846 crossref_primary_10_1152_ajpgi_00298_2017 crossref_primary_10_1016_j_cgh_2019_09_021 crossref_primary_10_1016_j_intimp_2018_09_005 crossref_primary_10_1097_MPG_0000000000002770 crossref_primary_10_1016_j_intimp_2020_106288 crossref_primary_10_1007_s10620_023_08122_w crossref_primary_10_1016_j_jep_2023_117503 crossref_primary_10_1016_j_cgh_2018_08_060 crossref_primary_10_1093_ibd_izy381 crossref_primary_10_1038_s41575_019_0261_4 crossref_primary_10_1016_j_immuni_2020_10_018 crossref_primary_10_1053_j_gastro_2022_07_004 crossref_primary_10_1016_j_jff_2019_103614 crossref_primary_10_1007_s13679_019_00332_6 crossref_primary_10_1136_gutjnl_2023_329964 crossref_primary_10_1038_s41684_019_0438_z crossref_primary_10_1093_ibd_izz021 crossref_primary_10_1155_2018_5738068 crossref_primary_10_3389_fcimb_2022_1064537 crossref_primary_10_1038_s41467_021_24470_5 crossref_primary_10_3390_biom14091122 crossref_primary_10_1080_19490976_2024_2359515 crossref_primary_10_3390_cells8070719 crossref_primary_10_1042_CS20210778 crossref_primary_10_3389_fnut_2021_717925 crossref_primary_10_1016_j_jpha_2024_01_008 crossref_primary_10_22416_1382_4376_2021_31_1_20_30 crossref_primary_10_3390_app11167622 crossref_primary_10_1080_17474124_2021_1840352 crossref_primary_10_1093_ibd_izab179 crossref_primary_10_1016_j_intimp_2024_112416 crossref_primary_10_1111_den_14659 crossref_primary_10_1242_dmm_049332 crossref_primary_10_1172_JCI120261 crossref_primary_10_1016_j_molmet_2021_101183 crossref_primary_10_1186_s13287_019_1246_5 crossref_primary_10_3390_nu13020642 crossref_primary_10_3748_wjg_v29_i36_5254 crossref_primary_10_1080_14786419_2024_2435535 crossref_primary_10_1111_apt_18027 crossref_primary_10_1021_acs_jafc_9b06294 crossref_primary_10_1016_j_gie_2018_08_006 crossref_primary_10_3389_fimmu_2024_1394654 crossref_primary_10_1016_j_gastha_2024_02_003 crossref_primary_10_3389_fnut_2022_718710 crossref_primary_10_1016_j_phrs_2020_105340 crossref_primary_10_3390_ijms23136944 crossref_primary_10_1039_D3FO01095C crossref_primary_10_3389_fimmu_2019_01441 crossref_primary_10_1038_s41584_023_00984_8 crossref_primary_10_1111_jsap_13506 crossref_primary_10_3390_proteomes6020017 crossref_primary_10_1016_j_jlr_2023_100486 crossref_primary_10_1111_jgh_16767 crossref_primary_10_1016_j_gastrohep_2021_02_022 crossref_primary_10_1042_CS20181081 crossref_primary_10_1111_apt_17241 crossref_primary_10_1093_ibd_izab239 crossref_primary_10_1186_s41232_017_0056_3 crossref_primary_10_1111_den_13023 crossref_primary_10_5056_jnm21018 crossref_primary_10_1093_ibd_izab230 crossref_primary_10_3390_nu11061239 crossref_primary_10_1186_s13256_024_05010_3 crossref_primary_10_1371_journal_ppat_1009989 crossref_primary_10_3389_fnagi_2022_861035 crossref_primary_10_1186_s12876_021_02035_6 crossref_primary_10_3390_metabo12100956 crossref_primary_10_4062_biomolther_2021_086 crossref_primary_10_1016_j_foodchem_2024_142391 crossref_primary_10_1016_j_intimp_2024_112900 crossref_primary_10_3233_NHA_170030 crossref_primary_10_1093_ecco_jcc_jjz027 crossref_primary_10_3389_fimmu_2022_895636 crossref_primary_10_1007_s10620_019_05580_z crossref_primary_10_1016_j_isci_2020_101798 crossref_primary_10_1038_s41385_021_00380_z crossref_primary_10_1093_ecco_jcc_jjaa085 crossref_primary_10_3389_fmed_2023_1221449 crossref_primary_10_3390_ijms24032971 crossref_primary_10_3748_wjg_v24_i6_706 crossref_primary_10_1016_j_jff_2024_106069 crossref_primary_10_1155_2021_5514075 crossref_primary_10_56871_CmN_W_2024_77_19_008 crossref_primary_10_1080_17474124_2023_2242772 crossref_primary_10_3390_microorganisms9081634 crossref_primary_10_3748_wjg_v29_i33_4991 crossref_primary_10_1016_j_gtc_2021_03_008 crossref_primary_10_1093_ibd_izae084 crossref_primary_10_1007_s10753_020_01259_0 crossref_primary_10_3390_diagnostics13071230 crossref_primary_10_1007_s10620_021_06888_5 crossref_primary_10_1016_j_actbio_2024_02_015 crossref_primary_10_1155_2018_9184093 crossref_primary_10_1093_ibd_izaf043 crossref_primary_10_1002_mnfr_202300509 crossref_primary_10_1186_s12951_022_01598_0 crossref_primary_10_3390_ijms232314776 crossref_primary_10_19110_1994_5655_2022_4_76_81 crossref_primary_10_5009_gnl220409 crossref_primary_10_1016_j_jnutbio_2021_108840 crossref_primary_10_1038_s41385_022_00550_7 crossref_primary_10_1016_j_cgh_2019_07_005 crossref_primary_10_3389_fimmu_2021_767456 crossref_primary_10_1016_j_jnutbio_2022_109254 crossref_primary_10_1177_2050640620977371 crossref_primary_10_7759_cureus_53699 crossref_primary_10_1186_s13020_024_01006_9 crossref_primary_10_1155_2022_9171436 crossref_primary_10_3390_cimb45070350 crossref_primary_10_1038_s41366_019_0492_z crossref_primary_10_1002_mnfr_201901269 crossref_primary_10_1016_j_cell_2020_09_009 crossref_primary_10_3748_wjg_v26_i26_3712 crossref_primary_10_1016_j_jep_2023_117105 crossref_primary_10_1080_21688370_2018_1463897 crossref_primary_10_3389_fnut_2021_798038 crossref_primary_10_2147_JIR_S407521 crossref_primary_10_1002_smll_202310851 crossref_primary_10_3390_ijms23062995 crossref_primary_10_1053_j_gastro_2022_10_014 crossref_primary_10_1016_j_jss_2023_08_027 crossref_primary_10_1152_ajpgi_00198_2023 crossref_primary_10_1016_j_gastre_2021_02_007 crossref_primary_10_1016_j_ijbiomac_2024_137847 crossref_primary_10_1016_j_actbio_2022_02_039 crossref_primary_10_1039_D3TB02302H crossref_primary_10_1177_1756284819880733 crossref_primary_10_2217_bmm_2020_0353 crossref_primary_10_1177_20420188231207348 crossref_primary_10_1016_j_msec_2018_08_033 crossref_primary_10_3390_nu13124259 crossref_primary_10_3390_ijms21051887 crossref_primary_10_1128_iai_00583_21 crossref_primary_10_3390_nu11030610 crossref_primary_10_14309_ajg_0000000000000183 crossref_primary_10_5817_CSF2023_5_233 crossref_primary_10_1021_acsami_3c14113 crossref_primary_10_1111_cpr_12547 crossref_primary_10_1177_1756284818769076 crossref_primary_10_1111_jcmm_14457 crossref_primary_10_3389_fphar_2020_594847 crossref_primary_10_1016_j_ijbiomac_2024_138122 crossref_primary_10_1016_j_jcmgh_2021_05_003 crossref_primary_10_1002_mnfr_202100639 crossref_primary_10_1016_j_gie_2018_02_038 crossref_primary_10_1039_D0NR00465K crossref_primary_10_3389_fphar_2022_883918 crossref_primary_10_1097_j_pain_0000000000002096 crossref_primary_10_1152_ajpgi_00159_2024 crossref_primary_10_1016_j_jcmgh_2021_01_020 |
Cites_doi | 10.3109/00365529709025101 10.1016/S0002-9270(01)04037-0 10.1136/gutjnl-2012-304066 10.1053/j.gastro.2013.06.010 10.1038/ncpgasthep0528 10.1097/MCG.0b013e3181fbdb8a 10.7869/tg.2012.3 10.1136/gut.47.3.404 10.1016/j.gie.2015.08.045 10.1038/ajg.2012.260 10.1097/MIB.0000000000000921 10.1136/gutjnl-2012-302093 10.1053/j.gastro.2014.07.046 10.1136/gutjnl-2011-300695 10.1038/nrgastro.2010.83 10.1002/ibd.20539 10.1016/j.cgh.2013.07.001 10.1016/j.dld.2015.01.148 10.1111/j.1572-0241.2002.05914.x 10.1016/j.gie.2013.04.042 10.1016/j.cgh.2012.02.029 10.1097/01.MIB.0000195385.19268.68 10.1016/j.crohns.2011.10.004 10.1038/ajg.2009.545 10.1111/apt.12262 10.1002/ibd.20520 10.1002/ibd.21925 10.1111/j.1365-2982.2012.01928.x 10.1053/j.gastro.2008.08.054 10.1038/ajg.2010.156 |
ContentType | Journal Article |
Copyright | 2017 AGA Institute AGA Institute Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2017 AGA Institute – notice: AGA Institute – notice: Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1053/j.gastro.2017.05.056 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1528-0012 |
EndPage | 731.e1 |
ExternalDocumentID | 28601482 10_1053_j_gastro_2017_05_056 S0016508517357311 1_s2_0_S0016508517357311 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 1B1 1CY 1P~ 1~5 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 AAEDT AAEDW AAFWJ AAIKJ AALRI AAQFI AAQOH AAQQT AAQXK AAXUO ABCQX ABDPE ABJNI ABLJU ABMAC ABOCM ABWVN ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AENEX AEVXI AFFNX AFHKK AFJKZ AFRHN AFTJW AGCQF AGHFR AGQPQ AI. AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN BELOY BR6 C5W CAG COF CS3 DU5 EBS EFJIC EFKBS EJD F5P FD8 FDB FEDTE FGOYB GBLVA HVGLF HZ~ IHE J1W J5H K-O KOM L7B M41 MO0 N4W N9A NQ- O9- OC. OHT ON0 P2P PC. QTD R2- ROL RPZ SEL SES SJN SSZ UDS UGJ UV1 VH1 WH7 X7M XH2 Y6R YQJ Z5R ZGI ZXP AAYOK ADPAM AFCTW PKN RIG AAIAV AGZHU AHPSJ ALXNB G8K TWZ ZA5 AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c470t-5fa9166caa2ee818cf35567fde32063cf9897e4f7fee0c19c4e01b809235eec83 |
ISSN | 0016-5085 1528-0012 |
IngestDate | Fri Jul 11 16:03:12 EDT 2025 Wed Feb 19 02:40:26 EST 2025 Tue Jul 01 02:08:58 EDT 2025 Thu Apr 24 23:04:13 EDT 2025 Fri Feb 23 02:41:20 EST 2024 Sun Feb 23 10:19:21 EST 2025 Tue Aug 26 20:03:19 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | CRP Intestinal Barrier Function CD ESR NSAID IBD CLS IQR TNF UC Leaky Gut eCLE IBS CLE Small Intestine C-reactive protein intestinal barrier function FL fluorescein leak endoscope based confocal laser endomicroscopy CDO CDAI Crohn's disease activity index Crohn's disease endoscopic index score inter-quartile range ulcerative colitis receiver operating characteristic leaky gut erythrocyte sedimentation rate irritable bowel syndrome ROC partial Mayo Crohn's disease Confocal Leak Score inflammatory bowel disease cell junction enhancement pMayo tumor necrosis factor small intestine cell drop out CDEIS CJE |
Language | English |
License | Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c470t-5fa9166caa2ee818cf35567fde32063cf9897e4f7fee0c19c4e01b809235eec83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-4909-2984 0000-0001-5944-3488 |
PMID | 28601482 |
PQID | 1908793928 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_1908793928 pubmed_primary_28601482 crossref_primary_10_1053_j_gastro_2017_05_056 crossref_citationtrail_10_1053_j_gastro_2017_05_056 elsevier_sciencedirect_doi_10_1053_j_gastro_2017_05_056 elsevier_clinicalkeyesjournals_1_s2_0_S0016508517357311 elsevier_clinicalkey_doi_10_1053_j_gastro_2017_05_056 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-09-01 |
PublicationDateYYYYMMDD | 2017-09-01 |
PublicationDate_xml | – month: 09 year: 2017 text: 2017-09-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Gastroenterology (New York, N.Y. 1943) |
PublicationTitleAlternate | Gastroenterology |
PublicationYear | 2017 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | McGuckin, Eri, Simms (bib8) 2009; 15 Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0; Mar 2011; Available at Schoepfer, Beglinger, Straumann (bib26) 2010; 105 Ballegaard, Bjergstrøm, Brøndum (bib4) 1997; 32 Leong, Nguyen, Meredith (bib19) 2008; 135 Fritscher-Ravens, Schuppan, Ellrichmann (bib9) 2014; 147 Vivinus-Nébot, Frin-Mathy, Bzioueche (bib20) 2014; 63 Chang, Ip, Yang (bib15) 2016; 83 Lewis, Chuai, Nessel (bib28) 2008; 14 Simrén, Axelsson, Gillberg (bib32) 2002; 97 Paramsothy, Leong (bib14) 2010; 7 Leong, Arshi, Chang (bib16) 2014; 29 Hanauer (bib1) 2006; 12 Geboes, Riddell, Ost (bib12) 2000; 47 Sartor (bib2) 2006; 3 Noth, Stüber, Häsler (bib31) 2012; 6 Kiesslich, Duckworth, Moussata (bib10) 2012; 61 Leong, Wong, Chen (bib11) 2012; 27 Lopez, Ford, Colombel (bib6) 2015; 47 Lovell, Ford (bib24) 2012; 10 Keohane, O'Mahony, O'Mahony (bib25) 2010; 105 Lahiff, Safaie, Awais (bib27) 2013; 37 Baars, Nuij, Oldenburg (bib13) 2012; 18 Halpin, Ford (bib3) 2012; 107 Martínez, Lobo, Pigrau (bib7) 2013; 62 Yang, Leong, Wong (bib18) 2013; 28 Alonso, Guilarte, Vicario (bib33) 2012; 24 Odenwald, Turner (bib22) 2013; 11 Jonefjall, Ohman, Simren (bib5) 2016; 22 Humphris, Swartz, Egan, Leong (bib34) 2012; 33 Liu, Mill, Wong (bib23) 2013; 77 Suenaert, Bulteel, Lemmens (bib30) 2002; 97 Liu, Madsen, Boulanger (bib17) 2011; 45 Accessed August 1, 2015. Sandborn, Feagan, Marano (bib29) 2014; 146 Fritscher-Ravens (10.1053/j.gastro.2017.05.056_bib9) 2014; 147 Baars (10.1053/j.gastro.2017.05.056_bib13) 2012; 18 Lewis (10.1053/j.gastro.2017.05.056_bib28) 2008; 14 Suenaert (10.1053/j.gastro.2017.05.056_bib30) 2002; 97 Geboes (10.1053/j.gastro.2017.05.056_bib12) 2000; 47 Lovell (10.1053/j.gastro.2017.05.056_bib24) 2012; 10 Leong (10.1053/j.gastro.2017.05.056_bib11) 2012; 27 Kiesslich (10.1053/j.gastro.2017.05.056_bib10) 2012; 61 Liu (10.1053/j.gastro.2017.05.056_bib23) 2013; 77 Martínez (10.1053/j.gastro.2017.05.056_bib7) 2013; 62 Halpin (10.1053/j.gastro.2017.05.056_bib3) 2012; 107 McGuckin (10.1053/j.gastro.2017.05.056_bib8) 2009; 15 Schoepfer (10.1053/j.gastro.2017.05.056_bib26) 2010; 105 Noth (10.1053/j.gastro.2017.05.056_bib31) 2012; 6 Sartor (10.1053/j.gastro.2017.05.056_bib2) 2006; 3 Lahiff (10.1053/j.gastro.2017.05.056_bib27) 2013; 37 Chang (10.1053/j.gastro.2017.05.056_bib15) 2016; 83 Humphris (10.1053/j.gastro.2017.05.056_bib34) 2012; 33 10.1053/j.gastro.2017.05.056_bib21 Hanauer (10.1053/j.gastro.2017.05.056_bib1) 2006; 12 Simrén (10.1053/j.gastro.2017.05.056_bib32) 2002; 97 Vivinus-Nébot (10.1053/j.gastro.2017.05.056_bib20) 2014; 63 Alonso (10.1053/j.gastro.2017.05.056_bib33) 2012; 24 Sandborn (10.1053/j.gastro.2017.05.056_bib29) 2014; 146 Leong (10.1053/j.gastro.2017.05.056_bib16) 2014; 29 Yang (10.1053/j.gastro.2017.05.056_bib18) 2013; 28 Keohane (10.1053/j.gastro.2017.05.056_bib25) 2010; 105 Leong (10.1053/j.gastro.2017.05.056_bib19) 2008; 135 Liu (10.1053/j.gastro.2017.05.056_bib17) 2011; 45 Lopez (10.1053/j.gastro.2017.05.056_bib6) 2015; 47 Odenwald (10.1053/j.gastro.2017.05.056_bib22) 2013; 11 Ballegaard (10.1053/j.gastro.2017.05.056_bib4) 1997; 32 Paramsothy (10.1053/j.gastro.2017.05.056_bib14) 2010; 7 Jonefjall (10.1053/j.gastro.2017.05.056_bib5) 2016; 22 |
References_xml | – volume: 7 start-page: 366 year: 2010 end-page: 368 ident: bib14 article-title: Endoscopy: Fluorescein contrast in confocal laser endomicroscopy publication-title: Nat Rev Gastroenterol Hepatol – volume: 27 start-page: 109 year: 2012 ident: bib11 article-title: Intestinal mucosal leakage is detected using in vivo confocal endomicroscopy in macroscopically-normal Crohn's disease and ulcerative colitis publication-title: J Gastroenterol Hepatol – volume: 47 start-page: 404 year: 2000 end-page: 409 ident: bib12 article-title: A reproducible grading scale for histological assessment of inflammation in ulcerative colitis publication-title: Gut – reference: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0; Mar 2011; Available at: – volume: 14 start-page: 1660 year: 2008 end-page: 1666 ident: bib28 article-title: Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis publication-title: Inflamm Bowel Dis – volume: 146 start-page: 96 year: 2014 end-page: 109 ident: bib29 article-title: PURSUIT-Maintenance Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis publication-title: Gastroenterology – volume: 10 start-page: 712 year: 2012 end-page: 721 ident: bib24 article-title: Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis publication-title: Clin Gastroenterol Hepatol – volume: 37 start-page: 786 year: 2013 end-page: 794 ident: bib27 article-title: The Crohn’s disease activity index (CDAI) is similarly elevated in patients with Crohn’s disease and in patients with irritable bowel syndrome publication-title: Aliment Pharmacol Ther – volume: 62 start-page: 1160 year: 2013 end-page: 1168 ident: bib7 article-title: Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier publication-title: Gut – volume: 107 start-page: 1474 year: 2012 end-page: 1482 ident: bib3 article-title: Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis publication-title: Am J Gastroenterol – volume: 18 start-page: 1634 year: 2012 end-page: 1640 ident: bib13 article-title: Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation publication-title: Inflamm Bowel Dis – volume: 3 start-page: 390 year: 2006 end-page: 407 ident: bib2 article-title: Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis publication-title: Nat Clin Pract Gastroenterol Hepatol – volume: 47 start-page: 356 year: 2015 end-page: 364 ident: bib6 article-title: Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: meta-analysis of placebo-controlled trials publication-title: Dig Liver Dis – volume: 12 start-page: S3 year: 2006 end-page: S9 ident: bib1 article-title: Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities publication-title: Inflamm Bowel Dis – volume: 33 start-page: 9 year: 2012 end-page: 20 ident: bib34 article-title: Status of confocal laser endomicroscopy in gastrointestinal disease publication-title: Trop Gastroenterol – volume: 97 start-page: 389 year: 2002 end-page: 396 ident: bib32 article-title: Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors publication-title: Am J Gastroenterol – volume: 77 start-page: S206 year: 2013 ident: bib23 article-title: Intestinal barrier dysfunction measured with confocal endomicroscopy in macroscopically normal mucosa can predict requirement for treatment escalation publication-title: Gastrointest Endosc – volume: 105 start-page: 162 year: 2010 end-page: 169 ident: bib26 article-title: Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI publication-title: Am J Gastroenterol – volume: 11 start-page: 1075 year: 2013 end-page: 1083 ident: bib22 article-title: Intestinal permeability defects: is it time to treat? publication-title: Clin Gasroenterol Hepatol – volume: 29 start-page: 11 year: 2014 ident: bib16 article-title: Acute tumour necrosis factor administration induces transient epithelial cell shedding, mucosal leak and neutrophil recruitment to the gut in a mouse model publication-title: J Gastroenterol Hepatol – volume: 28 start-page: 28 year: 2013 ident: bib18 article-title: Intestinal barrier dysfunction as identified by confocal endomicroscopy in macroscopically normal terminal is useful in detecting inflammatory bowel disease and predicting requirements for treatment escalation [abstract] publication-title: J Gastroenterol Hepatol – reference: . Accessed August 1, 2015. – volume: 15 start-page: 100 year: 2009 end-page: 113 ident: bib8 article-title: Intestinal barrier dysfunction in inflammatory bowel diseases publication-title: Inflamm Bowel Dis – volume: 135 start-page: 1870 year: 2008 end-page: 1876 ident: bib19 article-title: In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease publication-title: Gastroenterology – volume: 83 start-page: 785 year: 2016 end-page: 791 ident: bib15 article-title: The learning curve, interobserver, and intraobserver agreement of endoscopic confocal laser endomicroscopy in the assessment of mucosal barrier defects publication-title: Gastrointest Endosc – volume: 6 start-page: 464 year: 2012 end-page: 469 ident: bib31 article-title: Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease publication-title: J Crohns Colitis – volume: 45 start-page: 240 year: 2011 end-page: 245 ident: bib17 article-title: Mind the gaps: confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease publication-title: J Clin Gastroenterol – volume: 24 start-page: 740 year: 2012 end-page: 746 ident: bib33 article-title: Acute experimental stress evokes a differential gender-determined increase in human intestinal macromolecular permeability publication-title: Neurogastroenterol Motil – volume: 97 start-page: 2000 year: 2002 end-page: 2004 ident: bib30 article-title: Anti–tumor necrosis factor treatment restores the gut barrier in Crohn’s disease publication-title: Am J Gastroenterol – volume: 22 start-page: 2630 year: 2016 end-page: 2640 ident: bib5 article-title: IBS-like symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological well-being publication-title: Inflamm Bowel Dis – volume: 61 start-page: 1146 year: 2012 end-page: 1153 ident: bib10 article-title: Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease publication-title: Gut – volume: 105 start-page: 1789 year: 2010 end-page: 1794 ident: bib25 article-title: Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? publication-title: Am J Gastroenterol – volume: 32 start-page: 569 year: 1997 end-page: 571 ident: bib4 article-title: Self-reported food intolerance in chronic inflammatory bowel disease publication-title: Scand J Gastroenterol – volume: 147 start-page: 1012 year: 2014 end-page: 1020 ident: bib9 article-title: Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome publication-title: Gastroenterology – volume: 63 start-page: 744 year: 2014 end-page: 752 ident: bib20 article-title: Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation publication-title: Gut – volume: 32 start-page: 569 year: 1997 ident: 10.1053/j.gastro.2017.05.056_bib4 article-title: Self-reported food intolerance in chronic inflammatory bowel disease publication-title: Scand J Gastroenterol doi: 10.3109/00365529709025101 – ident: 10.1053/j.gastro.2017.05.056_bib21 – volume: 97 start-page: 389 year: 2002 ident: 10.1053/j.gastro.2017.05.056_bib32 article-title: Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors publication-title: Am J Gastroenterol doi: 10.1016/S0002-9270(01)04037-0 – volume: 63 start-page: 744 year: 2014 ident: 10.1053/j.gastro.2017.05.056_bib20 article-title: Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation publication-title: Gut doi: 10.1136/gutjnl-2012-304066 – volume: 27 start-page: 109 issue: Suppl 4 year: 2012 ident: 10.1053/j.gastro.2017.05.056_bib11 article-title: Intestinal mucosal leakage is detected using in vivo confocal endomicroscopy in macroscopically-normal Crohn's disease and ulcerative colitis publication-title: J Gastroenterol Hepatol – volume: 146 start-page: 96 year: 2014 ident: 10.1053/j.gastro.2017.05.056_bib29 article-title: PURSUIT-Maintenance Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.06.010 – volume: 3 start-page: 390 year: 2006 ident: 10.1053/j.gastro.2017.05.056_bib2 article-title: Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis publication-title: Nat Clin Pract Gastroenterol Hepatol doi: 10.1038/ncpgasthep0528 – volume: 29 start-page: 11 issue: Suppl 2 year: 2014 ident: 10.1053/j.gastro.2017.05.056_bib16 article-title: Acute tumour necrosis factor administration induces transient epithelial cell shedding, mucosal leak and neutrophil recruitment to the gut in a mouse model publication-title: J Gastroenterol Hepatol – volume: 45 start-page: 240 year: 2011 ident: 10.1053/j.gastro.2017.05.056_bib17 article-title: Mind the gaps: confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease publication-title: J Clin Gastroenterol doi: 10.1097/MCG.0b013e3181fbdb8a – volume: 33 start-page: 9 year: 2012 ident: 10.1053/j.gastro.2017.05.056_bib34 article-title: Status of confocal laser endomicroscopy in gastrointestinal disease publication-title: Trop Gastroenterol doi: 10.7869/tg.2012.3 – volume: 47 start-page: 404 year: 2000 ident: 10.1053/j.gastro.2017.05.056_bib12 article-title: A reproducible grading scale for histological assessment of inflammation in ulcerative colitis publication-title: Gut doi: 10.1136/gut.47.3.404 – volume: 83 start-page: 785 year: 2016 ident: 10.1053/j.gastro.2017.05.056_bib15 article-title: The learning curve, interobserver, and intraobserver agreement of endoscopic confocal laser endomicroscopy in the assessment of mucosal barrier defects publication-title: Gastrointest Endosc doi: 10.1016/j.gie.2015.08.045 – volume: 107 start-page: 1474 year: 2012 ident: 10.1053/j.gastro.2017.05.056_bib3 article-title: Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis publication-title: Am J Gastroenterol doi: 10.1038/ajg.2012.260 – volume: 22 start-page: 2630 year: 2016 ident: 10.1053/j.gastro.2017.05.056_bib5 article-title: IBS-like symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological well-being publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000000921 – volume: 62 start-page: 1160 year: 2013 ident: 10.1053/j.gastro.2017.05.056_bib7 article-title: Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier publication-title: Gut doi: 10.1136/gutjnl-2012-302093 – volume: 147 start-page: 1012 year: 2014 ident: 10.1053/j.gastro.2017.05.056_bib9 article-title: Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.07.046 – volume: 61 start-page: 1146 year: 2012 ident: 10.1053/j.gastro.2017.05.056_bib10 article-title: Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease publication-title: Gut doi: 10.1136/gutjnl-2011-300695 – volume: 7 start-page: 366 year: 2010 ident: 10.1053/j.gastro.2017.05.056_bib14 article-title: Endoscopy: Fluorescein contrast in confocal laser endomicroscopy publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2010.83 – volume: 15 start-page: 100 year: 2009 ident: 10.1053/j.gastro.2017.05.056_bib8 article-title: Intestinal barrier dysfunction in inflammatory bowel diseases publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.20539 – volume: 11 start-page: 1075 year: 2013 ident: 10.1053/j.gastro.2017.05.056_bib22 article-title: Intestinal permeability defects: is it time to treat? publication-title: Clin Gasroenterol Hepatol doi: 10.1016/j.cgh.2013.07.001 – volume: 47 start-page: 356 year: 2015 ident: 10.1053/j.gastro.2017.05.056_bib6 article-title: Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: meta-analysis of placebo-controlled trials publication-title: Dig Liver Dis doi: 10.1016/j.dld.2015.01.148 – volume: 97 start-page: 2000 year: 2002 ident: 10.1053/j.gastro.2017.05.056_bib30 article-title: Anti–tumor necrosis factor treatment restores the gut barrier in Crohn’s disease publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2002.05914.x – volume: 77 start-page: S206 year: 2013 ident: 10.1053/j.gastro.2017.05.056_bib23 article-title: Intestinal barrier dysfunction measured with confocal endomicroscopy in macroscopically normal mucosa can predict requirement for treatment escalation publication-title: Gastrointest Endosc doi: 10.1016/j.gie.2013.04.042 – volume: 10 start-page: 712 year: 2012 ident: 10.1053/j.gastro.2017.05.056_bib24 article-title: Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2012.02.029 – volume: 12 start-page: S3 issue: Suppl 1 year: 2006 ident: 10.1053/j.gastro.2017.05.056_bib1 article-title: Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities publication-title: Inflamm Bowel Dis doi: 10.1097/01.MIB.0000195385.19268.68 – volume: 6 start-page: 464 year: 2012 ident: 10.1053/j.gastro.2017.05.056_bib31 article-title: Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2011.10.004 – volume: 105 start-page: 162 year: 2010 ident: 10.1053/j.gastro.2017.05.056_bib26 article-title: Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI publication-title: Am J Gastroenterol doi: 10.1038/ajg.2009.545 – volume: 37 start-page: 786 year: 2013 ident: 10.1053/j.gastro.2017.05.056_bib27 article-title: The Crohn’s disease activity index (CDAI) is similarly elevated in patients with Crohn’s disease and in patients with irritable bowel syndrome publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12262 – volume: 14 start-page: 1660 year: 2008 ident: 10.1053/j.gastro.2017.05.056_bib28 article-title: Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.20520 – volume: 18 start-page: 1634 year: 2012 ident: 10.1053/j.gastro.2017.05.056_bib13 article-title: Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.21925 – volume: 24 start-page: 740 year: 2012 ident: 10.1053/j.gastro.2017.05.056_bib33 article-title: Acute experimental stress evokes a differential gender-determined increase in human intestinal macromolecular permeability publication-title: Neurogastroenterol Motil doi: 10.1111/j.1365-2982.2012.01928.x – volume: 28 start-page: 28 issue: Suppl 2 year: 2013 ident: 10.1053/j.gastro.2017.05.056_bib18 article-title: Intestinal barrier dysfunction as identified by confocal endomicroscopy in macroscopically normal terminal is useful in detecting inflammatory bowel disease and predicting requirements for treatment escalation [abstract] publication-title: J Gastroenterol Hepatol – volume: 135 start-page: 1870 year: 2008 ident: 10.1053/j.gastro.2017.05.056_bib19 article-title: In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2008.08.054 – volume: 105 start-page: 1789 year: 2010 ident: 10.1053/j.gastro.2017.05.056_bib25 article-title: Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? publication-title: Am J Gastroenterol doi: 10.1038/ajg.2010.156 |
SSID | ssj0009381 |
Score | 2.6161919 |
Snippet | Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether... Abstract Background & Aims Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 723 |
SubjectTerms | Adult Blood Sedimentation C-Reactive Protein - metabolism Case-Control Studies CLE Colitis, Ulcerative - diagnostic imaging Colitis, Ulcerative - physiopathology Colonoscopy Crohn Disease - diagnostic imaging Crohn Disease - physiopathology Female Gastroenterology and Hepatology Humans Intestinal Barrier Function Intestinal Mucosa - metabolism Intravital Microscopy Leaky Gut Male Microscopy, Confocal Middle Aged Permeability Prospective Studies Severity of Illness Index Small Intestine Symptom Assessment Wound Healing |
Title | Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0016508517357311 https://www.clinicalkey.es/playcontent/1-s2.0-S0016508517357311 https://dx.doi.org/10.1053/j.gastro.2017.05.056 https://www.ncbi.nlm.nih.gov/pubmed/28601482 https://www.proquest.com/docview/1908793928 |
Volume | 153 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZKJyFeEHfKTUbircpwLo6Tx23ANsRgYhvszUpdewytSdWmQvAD-Cn8Ts6J7SaIVhtIVVUlcaL0fPa5-PNnQl7oMFHKhBpyk7AIkkjkwWhsVJDCaJipECljWO84eJ_unSRvT_lpr_erw1pa1KNN9WPlupL_sSocA7viKtl_sOzypnAAfoN94RssDN9XsvE-9OVzJJBjXQ_6KkaWhzDUaiu-jb29tDtaWSGHD-VZhaWB7eqbvhgefZ9M62rSEGIPrbwqsmHrL3A7A0CZ2Al4e_ErO5FjeRnIcneixN7zufh2t5jXswp1PmdW3GnFZj_DME-69d0dX7PGyeaWIOS4wh8XUz2rh8tS0Odi3lQiG4IueDdI9dtK7_7Urj9q9jDvFjTASXrGFvgjNwijajYL_xylraawg2PcGXOFXbD8ly9gzYYeXzfPmjdHFp8VabVC5h14TCcNPqIsxfJq1HrGJV_Rn7pGNiJIR6I-2djdfvdpq5V3hsDHL8zk8ctVD0XZaXebdTHQuhyniXWOb5GbLkmhWxZxt0lPl3fI9QNHw7hLfnrg0RZ4tAs82gEerSvqgEcbLFEPPHpeUg88isCjXeC5ix3wKACPOuBRB7x75OTN6-OdvcBt6BGoRLA64KaAbCRVRRFpDZGiMhDtpsKMdRxBqKxMnuVCJ0YYrZkKc5VoFo4yBkkI11pl8X3SL6tSPyRUQBRlsmJcxEWcMD3OjWC4d1GquRnziA9I7P9iqZzaPW66ciEb1gWPIeu1NpJoI8k4fNIBCZatplbt5ZLrubee9CuZwfdKgOAl7cSqdnruBpe5DOU8kkweYUrGMS0SMRdxGHZbuhjZxr5XeOZzDy8JLgTnBYtSVwt4Vs4ycNN5lA3IA4u75dt7yD5ae-YxudH24iekX88W-ikE6vXomeslvwHEBOvG |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impaired+Intestinal+Permeability+Contributes+to+Ongoing+Bowel+Symptoms+in+Patients+With+Inflammatory+Bowel+Disease+and+Mucosal+Healing&rft.jtitle=Gastroenterology+%28New+York%2C+N.Y.+1943%29&rft.au=Chang%2C+Jeff&rft.au=Leong%2C+Rupert+W&rft.au=Wasinger%2C+Valerie+C&rft.au=Ip%2C+Matthew&rft.date=2017-09-01&rft.eissn=1528-0012&rft.volume=153&rft.issue=3&rft.spage=723&rft_id=info:doi/10.1053%2Fj.gastro.2017.05.056&rft_id=info%3Apmid%2F28601482&rft.externalDocID=28601482 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0016-5085&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0016-5085&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0016-5085&client=summon |